Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%

China’s E-bike Brands Going Global: A Review of 26 Leading Players

With the global e-bike market continuing to expand, Chinese e-bike companies are gradually shifting from being a manufacturing powerhouse to becoming a meaningful force in global competition. This article reviews a group of Chinese e-bike players and examines their overseas positioning and market entry paths—looking at how Chinese brands are securing a foothold in the next wave of globalization.

Hypershell (极壳科技) Secures $50 Million Series B+ Funding Co-Led by Ant Group (蚂蚁集团) and Meituan Dragonball Capital (美团龙珠), Accelerating Global Expansion of Consumer-Grade Exoskeletons

Consumer-grade exoskeleton startup Hypershell (极壳科技) announced the completion of its $50 million Series B+ financing round co-led by Ant Group (蚂蚁集团) and Meituan DragonBall (美团龙珠), bringing its total Series B series funding to $120 million to accelerate its global leadership in human-augmentation robotics.

Unpacking China | Key Chinese Firms to Watch This Week （10/05/2026-16/05/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

"Bowintec" completed a Pre-A financing round of nearly 300 million RMB, accelerating the large-scale implementation of industrial embodied intelligence.

Boyuan Capital, the market-oriented investment platform under Bosch, and GalaxyBot, a leading company in embodied intelligence, jointly incubated a joint venture — Bowintec (博银合创), which announced the completion of a Pre-A financing round, raising nearly 300 million RMB.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?